This is an overview of the USAID/Kyrgyz Republic FY 2024 Tuberculosis (TB) Roadmap, implemented with the FY 2023 budget. Through the annual TB Roadmap process, USAID has worked with implementing partners (IPs) and national and international TB stakeholders involved in TB prevention and care in the country.

TABLES

The following tables illustrate the distribution by technical area of the USAID TB budget for Kyrgyz Republic that will be used for the implementation of Kyrgyz Republic’s FY24 TB Roadmap (Table 1) and the core indicators that will be used to monitor implementation of Kyrgyz Republic’s TB Roadmap and the country's progress towards the United Nations General Assembly High-Level Meeting on TB targets (UNGA targets) (Table 2).

Table 1: USAID Budget for Kyrgyz Republic per Technical Area

Technical AreaUSAID TB budgetUSAID Percentage of TB budget
REACH$1,400,00023%
CURE$2,000,00023%
PREVENT$500,0008%
INNOVATE$400,0007%
SUSTAIN$1,700,00028%
TOTAL BUDGET:$6,000,000100%

Table 2: TB Core Indicators in Kyrgyz Republic from 2016-2022 and Targets for 2023

#Name20162017201820192020202120222023*
REACH: Increased DS- and DR-TB case notification
1TB Detection87%87%87%87%62%61%53%70%
2Bacteriological Diagnosis Coverage (Pulmonary TB)58%71%62%61%63%67%66%68%
3Childhood TB Notifications407436310305180239333347
4Drug-Resistant TB Notifications1,3091,5061,8221,5771,0389188371,012
5Private Sector TB Notifications--------
6Contact Investigation Coverage**--85%84%100%100%97%-
CURE: High treatment success rate in DS- and DR-TB
7TB Treatment Success Rate***82%82%81%81%82%81%- 
8Drug-Resistant TB treatment Success Rate****51%-62%71%71%---
PREVENT: Prevent TB transmission and development
9TPT Coverage3508881,3951,7987058691,1773,247
SUSTAINABLE SYSTEMS: Commitment and sustainability
10Proportion of Domestic Financing for TB--52%49%61%52%58%-

*Projected Targets: This represents the United Nations General Assembly High-Level Meeting targets (UNGA targets)
**Contact Investigation Coverage: based on limited available data.
***TB Treatment Success Rate: newest data for 2021 cohort reported.
****Drug-Resistant TB Treatment Success Rate: newest data for 2020 cohort reported.